Hormone Peptides TRIZ Cases
- Recombinant NT-proBNP Antibody for High-Specificity Cardiac Detection
A recombinant antibody with optimized CDR binding improves NT-proBNP detection sensitivity and specificity for earlier heart failure diagnosis.
- Variant-Specific NT-proBNP Antibodies for Accurate Heart Failure Assays
Point mutations in NT-proBNP can disrupt standard assays; these variant-specific antibodies improve heart failure diagnosis by detecting R46H and E43D forms.
- Albumin-Binding Pramlintide Analogues for Longer Half-Life
Conjugating pramlintide analogues to albumin-binding moieties extends half-life while reducing amyloid fibril formation and preserving amylin activity.
- Anti-Kallidin Antibodies for Bradykinin B1 Receptor Blockade
Antibodies targeting kallidin and des-Arg10-kallidin block bradykinin B1 receptor binding to address inflammation, pain, and fibrosis.
- Oral Osteocalcin-Derived Peptides for Fat Metabolism Regulation
OCN-derived oral peptides reduce fat absorption, liver fat, and blood lipids to address NAFLD and related metabolic disorders with fewer side effects.
- Glycoengineered FSTL1 Composition for Cardiac Tissue Regeneration
Glycoengineered FSTL1 with O-linked glycosylation and no N-linked glycosylation supports cardiomyocyte survival, growth, and scar reduction.
- Tirzepatide Dose Titration After GLP-1 RA Treatment Failure
Gradual weekly tirzepatide titration helps patients who miss HbA1c or weight goals on GLP-1 RAs improve control with better tolerability.
- Amylin Analog Polypeptides With Extended Half-Life and Solubility
Sequence-modified amylin analogs improve solubility, thermal stability, and half-life to enable less frequent dosing with fewer side effects.
- Soluble PYY Analogues With Extended Half-Life at Neutral pH
Amino acid changes plus a half-life extending group improve PYY analogue solubility near pH 6-7 and prolong NPY2 receptor action for obesity treatment.
- Recombinant FSH Glycosylation With Human-Like α2,6 Sialylation
Human cell line production adds α2,6 and α2,3 sialylation to recombinant FSH, improving natural-like pharmacokinetics and activity.
- CRF2 Agonist Peptides With Extended Half-Life for Subcutaneous Therapy
Modified CRF2 agonist peptides extend half-life and stability, enabling once-daily subcutaneous dosing instead of continuous infusion.
- CRF2 Agonist Peptides With Extended Half-Life for Chronic Therapy
Modified UCN2-derived peptides improve stability and solubility, enabling once-daily subcutaneous CRF2 therapy instead of continuous infusion.
- Modified MIS Protein for Ovarian Reserve and Uterine Protection
Modified MIS protein arrests folliculogenesis to preserve ovarian reserve and protect ovarian and uterine tissue during chemotherapy.
- Cyclized Hepcidin Peptide Conjugates for Solubility and Half-Life
Cyclized hepcidin analogue conjugates improve solubility, stability, and half-life while preserving iron regulation for iron overload treatment.
- Hepcidin Mimetic Peptides for Sickle Cell Organ Damage
Modified hepcidin peptides target sickle cell complications by reducing spleen and liver size while improving blood cell indices.
- Stable hAMY3R Agonist Peptides With Reduced Fibrillation
Targeted amino acid substitutions and a methylene bridge improve hAMY3R agonist stability, reduce dimerization, and extend half-life.
- Hepcidin Peptide Analogues for Ferroportin Binding and Iron Control
Engineered hepcidin analogues improve solubility and synthesis while binding ferroportin to lower serum iron in iron overload diseases.